LAUSR

Herein, we report a case of a 27-year-old Black African woman with HIV-1/hepatitis B virus (HBV) coinfection, end-stage kidney disease and development of HIV and HBV drug resistance, successfully treated with tenofovir alafenamide (TAF). At first observation in February 2012, the patient showed CD4þ cell count1⁄4 462 cells/ml (23%, CD4þ/CD8 0.36), HIV RNA1⁄4 12467600 IU/ml, subtype 02-AG, HBV DNA1⁄4 2155000 IU/ml, HBV genotype E, quantitative HBsAg1⁄4 56437 IU/ml, serum creatinine (sCr)1⁄4 0.93 mg/dl. HIV drug resistance testing at baseline did not show any mutation. She started the following antiretroviral therapy (ART): efavirenz 800 mg/day, tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC). In June 2013, viral suppression for both HIV RNA and HBV DNA was achieved, but sCR increased up to 1.86 mg/dl and her estimated glomerular filtration (eGFR) by chronic kidney disease epidemiology collaboration creatinine equation fell to 43.3 ml/min.